Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | GAK | O14976 | 2/20 | 0.40 |
| ▸ | NEK2 | P51955 | 2/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5614288 | 0.88 | NOS1 (0.56) | NOS1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4413213 | 0.87 | PDE4A (0.45) | NOS1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5614223 | 0.87 | NOS1 (0.55) | NOS1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5478328 | 0.86 | NOS1 (0.53) | NOS1GAKNEK2MAP4K1MAP3K11 | |
| SCHEMBL5456950 | 0.85 | NOS1 (0.56) | NOS1GAKNEK2MAP4K1TGFBR1 | |
| SCHEMBL5472215 | 0.85 | NOS1 (0.56) | NOS1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5606918 | 0.85 | NOS1 (0.65) | NOS1GAKNEK2MAP4K1TGFBR1 | |
| SCHEMBL5469941 | 0.84 | NOS1 (0.56) | NOS1SLC6A2SLC6A4SLC6A3GAK | |
| SCHEMBL5472017 | 0.84 | NOS1 (0.56) | NOS1SLC6A2SLC6A4SLC6A3GAK | |
| SCHEMBL5462871 | 0.84 | NOS1 (0.59) | NOS1GAKNEK2MAP4K1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | NOS1 107/4885CYP2D6 799/4885SLC6A2 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.